Celyad Treats First Patient Of Second Cohort In NKG2D CAR T-Cell Phase I Study

(RTTNews) - Belgian biopharmaceutical company Celyad SA (CYAD) announced Tuesday the infusion of the first patient of the second cohort of its Phase I clinical trial evaluating its NKG2D CAR T-Cell therapy in acute myeloid leukaemia or AML and multiple myeloma or MM indications.

The Phase I/IIa trial is designed to assess the safety and feasibility of NKG2D CAR T-Cells, with secondary endpoints including clinical activity.

Data readouts from the first 12 patients treated in the Phase I portion are expected in mid-2016. Once the recommended dose is determined, the IIa phase of the trial will commence, with 12 additional patients treated at the recommended dose.

Christian Homsy, CEO of Celyad, said, "Once the safety evaluation is complete, we expect to continue enrolment in the study to further evaluate the therapy's safety and to determine an appropriate dose. Due to its unique ability to target ligands present on most cancers, we believe our NKG2D CAR T-Cells have potential as a new treatment option for patients with a broad range of cancer types, including haematological malignancies and various solid tumours."